cbdMD (NYSEAMERICAN:YCBD) Posts Earnings Results

cbdMD (NYSEAMERICAN:YCBD) announced its earnings results on Thursday. The company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.03) by ($0.08), FiscalAI reports. cbdMD had a negative return on equity of 33.60% and a negative net margin of 13.29%.The business had revenue of $5.55 million for the quarter, compared to analyst estimates of $5.69 million.

cbdMD Trading Down 5.5%

NYSEAMERICAN:YCBD traded down $0.03 during trading hours on Thursday, reaching $0.56. 197,695 shares of the company were exchanged, compared to its average volume of 1,020,979. The business has a 50 day moving average of $0.64 and a 200 day moving average of $0.74. cbdMD has a 1-year low of $0.47 and a 1-year high of $2.56.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in cbdMD stock. Jane Street Group LLC bought a new stake in cbdMD, Inc. (NYSEAMERICAN:YCBD) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm bought 51,141 shares of the company’s stock, valued at approximately $69,000. Jane Street Group LLC owned 0.49% of cbdMD as of its most recent SEC filing. 7.18% of the stock is currently owned by hedge funds and other institutional investors.

cbdMD Company Profile

cbdMD, Inc (NYSEAMERICAN: YCBD) is a Charlotte, North Carolina–based producer and distributor of hemp-derived cannabidiol (CBD) products. Since its founding in 2018, the company has focused on developing a diverse portfolio of wellness offerings designed for human and pet use. Its product range includes tinctures, capsules, gummies, topicals, and pet-specific formulations, each developed to comply with U.S. Food and Drug Administration (FDA) guidelines for hemp-derived substances.

The company operates a vertically integrated business model, sourcing U.S.-grown hemp and overseeing manufacturing processes in cGMP-certified facilities.